[go: up one dir, main page]

WO2007030580A3 - Neuroprotectants - Google Patents

Neuroprotectants Download PDF

Info

Publication number
WO2007030580A3
WO2007030580A3 PCT/US2006/034796 US2006034796W WO2007030580A3 WO 2007030580 A3 WO2007030580 A3 WO 2007030580A3 US 2006034796 W US2006034796 W US 2006034796W WO 2007030580 A3 WO2007030580 A3 WO 2007030580A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
neural
protecting
administering
excitotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034796
Other languages
French (fr)
Other versions
WO2007030580A2 (en
Inventor
Mary Stenzel-Poore
Susan Stevens
Roger Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of WO2007030580A2 publication Critical patent/WO2007030580A2/en
Publication of WO2007030580A3 publication Critical patent/WO2007030580A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of protecting cells against cytotoxic insults are provided. The methods involve administering a composition including an agent that binds to and activates a Toll-like receptor to a subject, optionally in combination with administering an ASIC inhibitor. The methods are applicable to the protection of neural and non-neural cells. For example, methods of protecting a neural cell against excitotoxic brain injury are provided. Methods for preparing medicaments for the prophylactic treatment of excitotoxic injury, ischemia and/or hypoxia are also provided. Also provided are compositions for use in the described methods.
PCT/US2006/034796 2005-09-09 2006-09-08 Neuroprotectants Ceased WO2007030580A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71588105P 2005-09-09 2005-09-09
US60/715,881 2005-09-09
US80183006P 2006-05-19 2006-05-19
US60/801,830 2006-05-19

Publications (2)

Publication Number Publication Date
WO2007030580A2 WO2007030580A2 (en) 2007-03-15
WO2007030580A3 true WO2007030580A3 (en) 2007-10-11

Family

ID=37836442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034796 Ceased WO2007030580A2 (en) 2005-09-09 2006-09-08 Neuroprotectants

Country Status (1)

Country Link
WO (1) WO2007030580A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130425A1 (en) * 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
JP2010536907A (en) 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー Methods for providing patients with specific immune responses in amyloidosis and protein aggregation disorders
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
EP2806028B1 (en) 2008-11-04 2017-07-12 InDex Pharmaceuticals AB Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
WO2017011863A1 (en) * 2015-07-17 2017-01-26 The University Of Queensland Neuroprotective agents derived from spider venom peptides
WO2019140236A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
SG11202006526YA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007743A2 (en) * 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007743A2 (en) * 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN XUANMAO ET AL: "The tarantula toxin psalmotoxin 1 inhibits acid-sensing ion channel (ASIC) 1a by increasing its apparent H+ affinity", JOURNAL OF GENERAL PHYSIOLOGY, vol. 126, no. 1, July 2005 (2005-07-01), pages 71 - 79, XP002433748, ISSN: 0022-1295 *
XIONG ZHI-GANG ET AL: "Neuroprotection in ischemia: Blocking calcium-permeable acid-sensing ion channels", CELL, vol. 118, no. 6, 17 September 2004 (2004-09-17), pages 687 - 698, XP002433749, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2007030580A2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
EP2322178A3 (en) Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
WO2007030581A3 (en) Neuroprotectants
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
IL207038A (en) Diazaspiro[5.5]undecane derivatives, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for treating or reducing the risk of an inflammatory disease or condition
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010110685A8 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2009031106A3 (en) Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008089151A3 (en) High dose film compositions and methods of preparation
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2002074056A3 (en) Allosteric adenosine receptor modulators
WO2008103847A3 (en) Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2010093789A8 (en) A composition comprising (-) -trans-3- (5, 6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2008079993A3 (en) Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
WO2007066150A3 (en) Transdermal administration of active agents for systemic effect
WO2007030580A3 (en) Neuroprotectants
WO2008142569A3 (en) Topical compositions containing magaldrate
IL207928A (en) Pharmaceutical composition comprising a methotrexate (mtx) active agent and a 2,2-anhydropyrimidine adjuvant for reducing mtx toxicity and use thereof in the preparation of medicaments

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06814265

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06814265

Country of ref document: EP

Kind code of ref document: A2